TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25799306

Group type: EXPERIMENTAL
Intervention: Integrative borderline personality disorder-oriented adolescent family therapy (I-BAFT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Individual drug counseling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: I-BAFT
Number of subjects: 40
Study: 24120551

Group type: EXPERIMENTAL
Intervention: Increased testosterone levels in men
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Fearless dominance (FD) in men
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Fearless dominance (FD) in women
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Self-centered impulsivity (SCI) in women
Number of subjects: 201

Group type: COMPARATOR
Intervention: Baseline testosterone concentrations
Number of subjects: 201

Group type: COMPARATOR
Intervention: Cortisol concentrations
Number of subjects: 201
Study: 22135493

Group type: EXPERIMENTAL
Intervention: NIV (using the Synchrony BiPAP device) for 6 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Routine pharmacological treatment (Control)
Number of subjects: 15
Study: 19024257

Group type: EXPERIMENTAL
Intervention: Violight toothbrush holder
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (rinsed toothbrushes in cold tap water)
Number of subjects: 25
Study: 16801034

Group type: EXPERIMENTAL
Intervention: Kinematic navigation system
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional manual methods
Number of subjects: 71
Study: 12671949

Group type: EXPERIMENTAL
Intervention: Piribedil 150 mg/day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 10881249

Group type: EXPERIMENTAL
Intervention: [11C]Flumazenil PET
Number of subjects: 16
Study: 9256323

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative ADM instillation (Group C)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Postoperative ADM instillation alone (Group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Postoperative ADM plus 5-FU (Group B)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative ADM plus 5-FU (Group D)
Number of subjects: 200
Study: 8497831

Group type: EXPERIMENTAL
Intervention: Theophylline (Phyllocontin; 350 mg twice daily)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol (Volmax; 8 mg twice daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3543093

Group type: EXPERIMENTAL
Intervention: Indoramin therapy (50 mg every 12 hours for 2 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30252699

Group type: EXPERIMENTAL
Intervention: Flexible Reinforced Laryngeal Mask Airway (FLMA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 132
Study: 29802820

Group type: EXPERIMENTAL
Intervention: 200g red raspberries (201 mg total (poly)phenols)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 400g red raspberries (403 mg total (poly)phenols)
Number of subjects: 10

Group type: COMPARATOR
Intervention: matched control drink
Number of subjects: 10
Study: 28032465

Group type: EXPERIMENTAL
Intervention: Lixisenatide before breakfast
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lixisenatide before main meal
Number of subjects: 69
Study: 25802966

Group type: EXPERIMENTAL
Intervention: Surface peroneal nerve stimulation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 23479592

Group type: EXPERIMENTAL
Intervention: 8 mg lycopene/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 21130359

Group type: EXPERIMENTAL
Intervention: Acupuncture as an adjunct therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 9
Study: 18230264

Group type: EXPERIMENTAL
Intervention: EndoButton CL
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cross-pin fixation
Number of subjects: 56
Study: 16802251

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) performed 11 times per week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Ctrl) group (non-exercising)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (RVE and Ctrl)
Number of subjects: 20
Study: 14608833

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg daily for 6 months
Number of subjects: 20
Study: 12629084

Group type: EXPERIMENTAL
Intervention: Soy protein (SP) 40 g daily for 3 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Milk-based protein (MBP) 40 g daily for 3 months
Number of subjects: 71
Study: 12080805

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (15 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycine supplementation (25 g daily)
Number of subjects: 0
Study: 8649051

Group type: EXPERIMENTAL
Intervention: ATRA (all-trans retinoic acid) plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study: 1754467

Group type: EXPERIMENTAL
Intervention: IVIgG 400 mg/kg b.w. on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months (group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CyA 5‐10/kg b.w. by mouth in two daily doses for a period between 6 and 18 months (group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group A
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IVIgG and CyA (group B and C)
Number of subjects: 30
Study: 6626436

Group type: EXPERIMENTAL
Intervention: diclofensine 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: diclofensine 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: desmethylimipramine (DMI) 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 3921328

Group type: EXPERIMENTAL
Intervention: Simethicone (two tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (two tablets)
Number of subjects: 0
Study: 30893070

Group type: EXPERIMENTAL
Intervention: Amino acid supplement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30117795

Group type: EXPERIMENTAL
Intervention: Cell Saver (CS)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No Cell Saver (NCS)
Number of subjects: 95
Study: 26047963

Group type: EXPERIMENTAL
Intervention: High flavanol drink (494 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low flavanol drink (23 mg)
Number of subjects: 18
Study: 24296869

Group type: EXPERIMENTAL
Intervention: Ivabradine (5 mg b.i.d.)
Number of subjects: 221

Group type: COMPARATOR
Intervention: β-blockers (carvedilol 6.25 mg b.i.d. or bisoprolol 1.25 mg b.i.d.)
Number of subjects: 221
Study: 21439002

Group type: EXPERIMENTAL
Intervention: Web-based program
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Traditional face-to-face program
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 18313445

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 5996
Study: 16579996

Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg administered 24 hours after UAE
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no goserelin)
Number of subjects: 26
Study: 12948416

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 microg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl 20 microg/kg
Number of subjects: 45
Study: 10869739

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Conventional Three-Dimensional Conformal Radiation Therapy (3D-CRT)
Number of subjects: 232
Study: 9203444

Group type: EXPERIMENTAL
Intervention: trIGT
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: pIGT
Number of subjects: 87

Group type: COMPARATOR
Intervention: N-IGT
Number of subjects: 87

Group type: COMPARATOR
Intervention: IGT-D
Number of subjects: 87

Group type: COMPARATOR
Intervention: IGT-IGT
Number of subjects: 87

Group type: COMPARATOR
Intervention: N-N
Number of subjects: 87
Study: 8174949

Group type: EXPERIMENTAL
Intervention: Successful eradication of H pylori in 12 patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Unsuccessful eradication of H pylori in 22 patients
Number of subjects: 34
Study: 3780284

Group type: EXPERIMENTAL
Intervention: 12 mg betahistine dihydrochloride
Number of subjects: 88

Group type: COMPARATOR
Intervention: 15 mg cinnarizine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cinnarizine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 88
Study: 30088562

Group type: EXPERIMENTAL
Intervention: Mini-implant assisted helical uprighting spring (MIA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional helical uprighting spring (CA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MIA
Number of subjects: 20

Group type: COMPARATOR
Intervention: CA
Number of subjects: 20
Study: 27809874

Group type: EXPERIMENTAL
Intervention: SIT plus 30 min of moderate-intensity treadmill walking in the morning (ONE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SIT plus six hourly 5-min microbouts of moderate-intensity treadmill walking (MICRO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6 h of uninterrupted sitting (SIT)
Number of subjects: 30
Study: 25037462

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 70

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fibrin sealant and Manual compression
Number of subjects: 70
Study: 22012170

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 I.U.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20847753

Group type: EXPERIMENTAL
Intervention: Acrylic hydrophobic AcrySof SA60AT IOLs
Number of subjects: 41

Group type: COMPARATOR
Intervention: Silicone Tecnis Z9000 IOLs
Number of subjects: 41
Study: 18455082

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for 7 years)
Number of subjects: 18882

Group type: COMPARATOR
Intervention: Placebo (daily for 7 years)
Number of subjects: 18882
Study: 16647439

Group type: EXPERIMENTAL
Intervention: Contrast medium administration during donor evaluation (coronary angiography or levography)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No contrast medium administration during donor evaluation
Number of subjects: 72
Study: 14520725

Group type: EXPERIMENTAL
Intervention: RDS infants
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 10736119

Group type: EXPERIMENTAL
Intervention: Resistive heating blanket set to 42 degrees C (107.6 degrees F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Reflective foil (passive insulation)
Number of subjects: 8
Study: 9178844

Group type: EXPERIMENTAL
Intervention: Ketamine (0.83 mg/ml, 6 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (injected 1 week after ketamine treatment)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (injected 2 weeks after ketamine treatment)
Number of subjects: 10
Study: 1389240

Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g at induction of anaesthesia and then CFX 750 mg b.i.d. for 4 days (Group A)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g and metronidazole (MTR) 1.0 g at induction of anaesthesia, then CFX 750 mg b.i.d. and MTR 500 mg qds for 4 days (Group B)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g and metronidazole (MTR) 1.0 g at induction of anaesthesia (Group C)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g on induction of anaesthesia (Group D)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g on induction of anaesthesia then CFX 750 mg bd for 2 days (Group E)
Number of subjects: 226
Study: 3901631

Group type: EXPERIMENTAL
Intervention: Hemosorption treatment (n=90)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No hemosorption treatment (n=50)
Number of subjects: 140
Study: 31032654

Group type: EXPERIMENTAL
Intervention: Nasal splint packing (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Merocel packing (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (30 patients)
Number of subjects: 60
Study: 26164214

Group type: EXPERIMENTAL
Intervention: Self-care intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care/attention control
Number of subjects: 134
Study: 23680441

Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS)
Number of subjects: 1673
Study: 21534705

Group type: EXPERIMENTAL
Intervention: Adding trials of joint absence or joint presence of events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding trials where one event occurs in the absence of another
Number of subjects: 0
Study: 18279877

Group type: EXPERIMENTAL
Intervention: Early oral intake (EOI) group - clear liquid drink given 2 hours after surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed oral intake (DOI) group - clear liquid drink given 8 hours after surgery
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early oral intake (EOI) group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed oral intake (DOI) group
Number of subjects: 200
Study: 17302256

Group type: EXPERIMENTAL
Intervention: Interferon plus ribavirin therapy
Number of subjects: 9
Study: 12898010

Group type: EXPERIMENTAL
Intervention: 5 mg B2036‐PEG
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10 mg B2036‐PEG
Number of subjects: 7
Study: 11885185

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)-coated implants
Number of subjects: 800

Group type: COMPARATOR
Intervention: Non-smokers (including those who quit)
Number of subjects: 800
Study: 8757209

Group type: EXPERIMENTAL
Intervention: Auranofin, 3 mg twice daily
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 1393459

Group type: EXPERIMENTAL
Intervention: Reversed grafts
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: In situ grafts
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Small vein grafts (< 4 mm in diameter)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Vein grafts (≥ 4 mm in diameter)
Number of subjects: 226
Study: 3903735

Group type: EXPERIMENTAL
Intervention: Nutrition counseling after withdrawal from drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dietary change after withdrawal from drugs (Group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued drug treatment (Group III)
Number of subjects: 0
Study: 30851861

Group type: COMPARATOR
Intervention: Intervention
Number of subjects: 228
Study: 28815329

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with Ribavirin
Number of subjects: 30
Study: 26705350

Group type: EXPERIMENTAL
Intervention: SAX
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: LAX
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OAX
Number of subjects: 220
Study: 24065417

Group type: EXPERIMENTAL
Intervention: Split-thickness skin grafts
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment (control)
Number of subjects: 100
Study: 22749332

Group type: EXPERIMENTAL
Intervention: Continuous oral suctioning (COS) using a saliva ejector connected to 100mmHg of suction.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group with conventional endotracheal tube without COS.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous oral suctioning (COS) using a saliva ejector.
Number of subjects: 27
Study: 20133408

Group type: EXPERIMENTAL
Intervention: Artesunate suppository
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17222282

Group type: EXPERIMENTAL
Intervention: CRA plus voucher-based incentives set at a high monetary value ($1995/12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CRA with vouchers set at a low monetary value ($499/12 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-value voucher condition
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Duration of abstinence achieved during treatment
Number of subjects: 100
Study: 15077095

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12068339

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg bid
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 9654222

Group type: EXPERIMENTAL
Intervention: 6 cm/6 cm electrode length combination
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 11 cm electrode in the right atrium
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 11 cm electrode in the coronary sinus
Number of subjects: 15
Study: 9247454

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (0.5, 1, 5, 10, or 25 micrograms/kg) administered once daily by intravenous bolus injection over 7 consecutive days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo administered once daily by intravenous bolus injection over 7 consecutive days
Number of subjects: 46
Study: 1657680

Group type: EXPERIMENTAL
Intervention: Mucolytic-antifoam solution (simethicone, acetylcysteine, sodium bicarbonate)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 6452806

Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg (single daily dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg (divided dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zimelidine (control group not specified)
Number of subjects: 0
Study: 31697010

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser plus topical tioconazole 28% for five sessions with 3 weeks interval
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fractional CO2 laser for five sessions with 3 weeks interval
Number of subjects: 120

Group type: COMPARATOR
Intervention: Topical tioconazole 28% for 16 weeks
Number of subjects: 120
Study: 30776777

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 32
Study: 29256407

Group type: EXPERIMENTAL
Intervention: Oral magnesium lactate (360 mg elemental magnesium)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23648350

Group type: EXPERIMENTAL
Intervention: Trans-umbilicus laparoendoscopic one-trocar surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: Trans-umbilicus and abdominal wall two-trocar laparoscopic surgery
Number of subjects: 78
Study: 20863419

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12 (BB-12) administered twice a day (daily dose of 10 billion colony-forming units) from 1-2 months to 8 months.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control tablet administered twice a day.
Number of subjects: 109
Study: 19529055

Group type: EXPERIMENTAL
Intervention: Education sessions with husbands
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Education sessions alone
Number of subjects: 442

Group type: COMPARATOR
Intervention: No education sessions (control)
Number of subjects: 442
Study: 17251278

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15789979

Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees toothbrush
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral‐B Indicator toothbrush
Number of subjects: 16

Group type: COMPARATOR
Intervention: Crest SpinBrush PRO toothbrush
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 16
Study: 11197284

Group type: EXPERIMENTAL
Intervention: Patients aged <60 years
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Patients aged >=60 years
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control subjects aged <60 years
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control subjects aged >=60 years
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall comparison of pharynx peak pressure
Number of subjects: 41
Study: 9266953

Group type: EXPERIMENTAL
Intervention: Glycosylated G-CSF (5 microg/kg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-glycosylated G-CSF
Number of subjects: 20
Study: 8345034

Group type: EXPERIMENTAL
Intervention: CGS 20 267 (0.02 mg to 30 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CGS 20 267 (0.02 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CGS 20 267 (30 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CGS 20 267 (10 mg and 30 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CGS 20 267 (up to 30 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CGS 20 267 (all doses)
Number of subjects: 18
Study: 3772617

Group type: EXPERIMENTAL
Intervention: Printed educational materials
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Audiocassette educational materials
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Videocassette educational materials
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control group (no educational materials mentioned)
Number of subjects: 635
Study: 31568235

Group type: EXPERIMENTAL
Intervention: Fenobam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29095743

Group type: EXPERIMENTAL
Intervention: Pictogram pillbox with text and pictogram instructions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard pillbox with text instructions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pictogram pillbox
Number of subjects: 30
Study: 27562916

Group type: EXPERIMENTAL
Intervention: Exenatide (acute infusion)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Liraglutide (1.8 mg daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 57